ArticleCureus2025
Unveiling the Spectrum of Liver Endurance in Systemic Lupus Erythematosus: A Single-Center Experience From Kashmir, India.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Systemic lupus erythematosus (SLE) presents myriad challenges to gastroenterologists, although clinically significant liver involvement is uncommon. Literature regarding liver involvement remains variable, and the scope to illuminate this issue is vast, necessitating further study. Aims and objectives The purpose of this study was to assess and categorize the liver involvement in SLE and to evaluate treatment response. Methods Our study was a retrospective observational study. Diagnosed cases of SLE referred to the Department of Gastroenterology were evaluated for liver involvement. Detailed history, clinical examination, and biochemical profile were recorded. Imaging, liver biopsy, and/or endoscopic gastroduodenoscopy were used as adjuncts wherever needed. After proper evaluation, patients were categorized according to liver involvement, and treatment response was assessed. Results Out of 96 patients with SLE referred to gastroenterology, 32 had liver abnormalities. Six (12.5%) patients had non-alcoholic fatty liver disease, four (12.5%) had nodular regenerative hyperplasia, two (6.25%) had lupus hepatitis, five (15.62%) had drug-induced liver injury, and one case each (3.12%) had hepatic infarction, hepatitis B, and hepatitis C. Autoimmune hepatitis (AIH) was seen in five (15.62%) patients, primary biliary cholangitis (PBC) was seen in one (3.12%), and AIH-PBC overlap was seen in three (9.375%) patients. Treatment was tailored according to the diagnosis, and response was assessed. One patient with hepatic infarction presenting as ALF died. Conclusion Liver perturbations may arise from basic diseases or side effects during treatment or unrelated factors. It is a multifaceted interplay between autoimmune mechanisms, vascular complications, and drug-related hepatotoxicity. Recognizing diverse presentations and understanding diagnostic intricacies are crucial for clinicians managing SLE patients with hepatic involvement, enabling better treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.